Hereditary breast cancer syndromes and clinical implications

Journal of Plastic, Reconstructive and Aesthetic Surgery

Volumn 62, Issue 2, 2009, Pages 181-189

  Majdak Paredes, E J ^a,b   Fatah, F ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

BRCA1; BRCA2; Breast reconstruction; Healthy mutation carriers; Hereditary breast cancer; Risk reducing mastectomy

Indexed keywords

BRCA2 PROTEIN; CHECKPOINT KINASE 2; TAMOXIFEN;

BREAST AREOLA; BREAST CANCER; BREAST RECONSTRUCTION; BREAST REDUCTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL FEATURE; FAMILIAL CANCER; GENE FUNCTION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; ONCOGENE; OVARIECTOMY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS MASTECTOMY; SYNDROME;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MAMMAPLASTY; MASTECTOMY; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PROTEIN-SERINE-THREONINE KINASES; RADIOTHERAPY, ADJUVANT;

EID: 58349120385     PISSN: 17486815     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjps.2008.07.012     Document Type: Review

References (93)

1. Office for National Statistics. Cancer Statistics registrations: registrations of cancer diagnosed in 2002, England. Series MB1 no.33 (2005), National Statistics, London
2. Newman B., Austin M.A., Lee M., et al. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A 85 (1988) 3044-3048
3. Claus E.B., Rish N., and Thompson W.D. Autosomal dominant inheritance of early onset breast cancer. Implication for risk prediction. Cancer 73 (1994) 643-651
4. Brocca P. Traite des tumeurs. Paris; 1866: pp. 151-155.
5. Smith A., Moran A., Boyd M., et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implication for screening?. J Med Genet 44 (2007) 10-15
6. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA 1. Science 266 (1994) 67-71
7. Wooster R., Bignell G., Lancaster J., et al. Identification of breast cancer susceptibility gene BRCS2. Nature 378 (1995) 789-792
8. Tavtigian S.V., Simard J., Rommens J., et al. The complete BRCA 2 gene and mutations chromosome 13q-linked kindreds. Nat Genet 12 (1996) 33-37
9. Evans D.G.R., Fentiman I.S., McPherson K., et al. Familial breast cancer. Br Med J 308 (1994) 183-187
10. Evans D.G.R., Cuzick J., and Howell A. Cancer genetics clinics. Eur J Cancer 32 (1996) 391-392
11. Thull D.S., and Vogel V.G. Recognition and management of hereditary breast cancer syndromes. Oncologist 9 (2004) 13-24
12. Ford D., Easton D.F., Bishop D.T., et al. Risk cancer in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. Lancet 343 (1994) 692-695
13. Ford D., Easton D.F., Stratron M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (1998) 676-689
14. Antoniou A., Pharoah P.D.P., Narod S., et al. Average risks of breast and ovarian cancer associated with mutations in BRCA1 and BRCA2 detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (2003) 1117-1130
15. Struewing J., Hartge P., Wacholder S., et al. The risk of breast cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 (1997) 1401-1407
16. Available from:. http://research.nhgri.nih.gov/bic/
17. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 349 (1997) 1505-1510
18. Skolnick M.H., Cannon-Albright L.A., Goldgar D.E., et al. Inheritance of proliferative breast disease in breast cancer kindreds. Science 250 (1990) 1715-1720
19. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry Cancer. 1993; 71: 1981-1991.
20. Schorge J.O., Muto M.G., Welch W.R., et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 90 (1998) 841-845
21. Giusti R.M., Rutter J.L., Duray P.H., et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 40 (2003) 787-792
22. Edwards S.M., Kote-Jarai Z., Meitz J., et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72 (2003) 1-12
23. Gómez-García E.B., Ambergen T., Blok M.J., et al. Patients with an uinclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation. J Clin Oncol 23 (2005) 2185-2190
24. Vink G.R., van Asperen C.J., Devilee P., et al. Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines. Eur J Hum Genet 13 (2005) 525-527
25. Quaresima B., Faniello M.C., Baudi F., et al. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo. Oncol Rep 16 (2006) 811-815
26. Chenevix-Trench G., Healey S., Lakhani S., et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66 (2006) 2019-2027
27. Majdak E.J., Devilee P., De Bock G.H., et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104 (2005) 1004-1012
28. Majdak E.J., De Bock G.H., Devilee P., et al. Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report. Eur J Cancer 41 (2005) 143-150
29. Welcsh P.L., Owens K.N., and King M.C. Insights into the function of BRCA1 and BRCA2. Trends Genet 16 (2000) 69-74
30. ElShamy W.M., and Livingston D.M. Identification of BRCA1-IRIS, a BRCA1 locus product. Nat Cell Biol 6 (2004) 954-967
31. Thompson M.E., Jensen R.A., Obermiller P.S., et al. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9 (1995) 444-450
32. Furuta S., Jiang X., Gu B., et al. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci U S A 102 (2005) 9176-9181
33. Whittemore A.S., Gong G., and Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60 (1997) 496-504
34. Petrucelli N., Daly M.B., Bars Culver J.O., et al. BRCA1 and BRCA2 hereditary breast/ovarian cancer. Available from:. Gene Rev (2005). www.geneclinics.org
35. Rubin S.C., Benjamin I., Behbakht K., et al. Clinical and pathological features of ovarian cancer in women with germ- line mutations of BRCA1. N Engl J Med 335 (1996) 1413-1416
36. Smith P., McGuffog L., Easton D.F., et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45 (2006) 646-655
37. Meijers-Heijboer H., van den Ouweland A., Klijn J., et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31 (2002) 55-59
38. Dong X., Wang L., Taniguchi K., et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72 (2003) 270-280
39. Vahteristo P., Tamminen A., Karvinen P., et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61 (2001) 5718-5722
40. Matsuoka S., Huang M., and Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282 (1998) 1893-1897
41. Bartkova J., Horejsi Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
42. Chehab N.H., Malikzay A., Appel M., et al. Chk2/hCds1 functions as a DNA damage checkpoint in G-1 by stabilizing p53. Genes Dev 14 (2000) 278-288
43. Lee J.S., Collins K.M., Brown A.L., et al. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404 (2000) 201-204
44. De Bock G.H., Schutte M., Krol-Warmedram E.M., et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 41 (2004) 731-735
45. Evans D.G.R., Burnell L.D., Hopwood P., et al. Perception of risk in women with a family history of breast cancer. Br J Cancer 67 (1993) 612-614
46. Sauven P. Guidelines for the management of women at increased familial risk of breast cancer. Eur J Cancer 40 (2004) 653-665
47. Evans D.G.R., Blair V., Greenhalgh R., et al. The impact of genetic counseling on risk perception in women with a family history of breast cancer. Br J Cancer 70 (1994) 934-938
48. Lerman C., Lustbader R., Rimer B., et al. Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst 87 (1995) 286-292
49. Bordelau L.J., Neligan P.C., and Lipa J.E. Management of the BRCA mutation mutation carrier or high risk patient. Clin Plast Surg 34 (2007) 15-27
50. Evans D.G.R., Lalloo F., Hopwood P., et al. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol 31 (2005) 1112-1118
51. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93 (2001) 1633-1637
52. Meijers-Heijboer H.B., van Geel, van Patten W.L., et al. Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med 345 (2001) 159-164
53. Ghosh K., and Hartmann L.C. Current status of prophylactic mastectomy. Oncology 16 (2002) 1319-1325
54. Fisher E.R., Fisher B., Sass R., et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 4). XI Bilateral Breast Cancer. Cancer 54 (1984) 3002-3011
55. Harris R.E., Lynch H.T., and Guirgis H.A. Familial breast cancer: risk to the contralateral breast. J Natl Cancer Inst 60 (1978) 955-960
56. Verhoog L.C., Berkelmans C.T., Seynaeve C., et al. Survival and tumor characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 351 (1998) 316-321
57. Robson M., Gilewski T., Haas B., et al. BRCA-associated breast cancer in young women. J Clin Oncol 16 (1998) 1642-1649
58. Bresser P.J., Seynaeve C., Van Gool A.R., et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg 117 (2006) 1675-1682 [discussion: 1683-4]
59. Metcalfe K.A., Semple J.L., and Narod S.A. Time to reconsider subcutaneous mastectomy for breast cancer prevention?. Lancet Oncol 6 (2005) 431-434
60. Spear S.L., Carter M.E., and Schwarz K. Prophylactic mastectomy: indications, options, and reconstructive alternatives. Plast Reconstr Surg 115 (2005) 891-909
61. Baasch M., Nielsen S.F., Engholm G., et al. Breast cancer incidence subsequent to surgical reduction of the female breast. Br J Cancer 73 (1996) 961-963
62. Brinton L.A., Persson I., Boice I.D., et al. Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden. Cancer 91 (2001) 478-483
63. Tarone R.E., Lipworth L., Young V.L., et al. Breast reduction surgery and breast cancer risk: does reduction mammoplasty have a role in primary prevention strategy for women at high risk of breast cancer?. Plast Reconstr Surg 113 (2004) 2104-2110
64. Orgill D.P., Iglehart J.D., and Gelman R. Discussion: breast reduction surgery and breast cancer risk: does reduction mammoplasty have a role in primary prevention strategies for women at high risk of breast cancer?. Plast Reconstr Surg 113 (2004) 2111-2112
65. Rebbeck T.R., Levin A.M., Eisen A., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 (1999) 1475-1479
66. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 346 (2002) 1616-1622
67. Kauff N.D., Satagopan J.M., Robson M.R., et al. Risk reducing salpingo-oophorectomy in carriers of BRCA1 and BRCA2 mutation. N Engl J Med 346 (2002) 1609-1615
68. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23 (2005) 7491-7496
69. Freeman B.S. Subcutaneous mastectomy for benign breast lesions with immediate or delayed prosthetic replacement. Plast Reconstr Surg 30 (1962) 676-682
70. Kroll S.S., Evans G.R., Reece G.P., et al. Comparison of resource costs between implant-based and TRAM flap breast reconstruction. Plast Reconstr Surg 97 (2002) 364-372
71. Alderman A.K., Wilkins E.G., Kim H.M., et al. Complications in postmastectomy breast reconstruction: two-year results of the Michigan Breast Reconstruction Outcome Study. Plast Reconstr Surg 109 (2002) 2265-2274
72. Armstrong R.W., Berkowitz R.L., and Bolding F. Infection following breast reconstruction. Ann Plast Surg 23 (1989) 284-288
73. Mansfield C. Effects of radiation therapy on wound healing after mastectomy. Clin Plast Surg 6 (1979) 19-26
74. Spear S.L. Primary implant reconstruction. In: Spear S.L. (Ed). Surgery of the breast: principles and art. 1st ed. (1998), Lippincott-Raven, Philadelphia 347-355
75. Handel N. The effect of silicon implants on the diagnosis, prognosis and treatment of breast cancer. Plast Reconstr Surg 120 (2007) 81S-93S
76. Handel N., and Silverstein M.J. Breast cancer diagnosis and prognosis in augmented women. Plast Reconstr Surg 118 (2006) 594-596
77. Fatah F. Extended latissimus dorsi flap in breast reconstruction. Oper Techn Plast Reconstr Surg 6 (1999) 138-149
78. Titley O.G., Spyrou G.E., and Fatah M.F. Preventing seroma in the latissimus dorsi flap donor site. Br J Plast Surg 50 (1997) 106-108
79. Mehrara B.J., Santoro T.D., Arcilla E., et al. Complications after microvascular breast reconstruction: experience with 1195 flaps. Plast Reconstr Surg 118 (2006) 1100-1109 [discussion: 1110-1]
80. Kroll S.S., Gherardini G., Martin J.E., et al. Fat necrosis in free and pedicled TRAM flaps. Plast Reconstr Surg 102 (1998) 1502-1507
81. Chang D.W., Reece G.P., Wang B., et al. Effect of smoking on complications in patients undergoing free TRAM flap breast reconstruction. Plast Reconstr Surg 105 (2000) 2374-2380
82. Chang D.W., Wang B., Rob G.L., et al. Effect of obesity on flap and donor site complications in free transverse rectus abdominis myocutaneous flap breast reconstruction. Plast Reconstr Surg 105 (2000) 1640-1648
83. Bonde C.T., Lund H., Fridberg M., et al. Abdominal strength after breast reconstruction using a free abdominal flap. J Plast Reconstr Aesthet Surg 60 (2007) 519-523
84. Blondeel P.N. One hundred free DIEP flap breast reconstructions: a personal experience. Br J Plast Surg 52 (1999) 104-111
85. Blondeel N., Vanderstraeten G.G., Monstrey S.J., et al. The donor site morbidity of free DIEP flaps and free TRAM flaps for breast reconstruction. Br J Plast Surg 50 (1997) 322-330
86. Mizgala C.L., Hartrampf Jr. C.R., and Bennett G.K. Assessment of the abdominal wall after pedicled TRAM flap surgery: 5- to 7-year follow-up of 150 consecutive patients. Plast Reconstr Surg 93 (1994) 988-1002 [discussion: 1003-4]
87. Kroll S.S., Schusterman M.A., Reece G.P., et al. Abdominal wall strength, bulging, and hernia after TRAM flap breast reconstruction. Plast Reconstr Surg 96 (1995) 616-619
88. Schusterman M.A., Kroll S.S., Miller M.J., et al. The free transverse rectus abdominis musculocutaneous flap for breast reconstruction: one center's experience with 211 consecutive cases. Ann Plast Surg 32 (1994) 234-241 [discussion: 241-2]
89. Allen R.J. DIEP versus TRAM for breast reconstruction. Plast Reconstr Surg 111 (2003) 2478
90. Chen L., Hartrampf C.R., and Bennet G.K. Successful pregnancies following TRAM flap surgery. [comment]. Plast Reconstr Surg 91 (1993) 69-71
91. Contant C.M., van Geel A.N., van der Holt B., et al. Morbidity of immediate breast reconstruction after mastectomy by subpectorally placed silicone prosthesis: the adverse effect of radiotherapy. Eur J Surg Oncol 26 (2000) 344-350
92. Vanderweyer E., and Deraemaecker R. Radiation therapy after immediate breast reconstruction with implants. Plast Reconstr Surg 106 (2000) 56-58
93. Spear S.L., and Onyewu C. Staged breast reconstruction with saline-filled implants in the irradiated breast: recent trends and therapeutic implications. Plast Reconstr Surg 105 (2000) 930-942